Two randomized, placebo-controlled studies comparedthe change from baseline FcεRI expression onplasmacytoid dendritic cells (pDC2s), bronchialmucosal IgE+ cells, and blood basophils, respectively,in patients with non-atopic asthma after 14-16 weeksof treatment with omalizumab. Here, IGHE is linked to atopic asthma.